Highlights of the RJBC 1501 Trial
The RJBC 1501 trial marks a significant milestone in the management of early-stage triple-negative breast cancer (TNBC). The primary findings indicate that the addition of carboplatin to a standard adjuvant regimen of epirubicin and cyclophosphamide followed by taxanes (EC-T) significantly improves clinical outcomes. Key highlights include:
1. A 34% reduction in the risk of disease recurrence or death (DFS HR, 0.66; 95% CI, 0.44 to 0.97).
2. A 39% reduction in the risk of distant metastasis (DDFS HR, 0.61; 95% CI, 0.38 to 0.98).
3. A profound 61% reduction in the risk of death (OS HR, 0.39; 95% CI, 0.16 to 0.94).
4. A safety profile characterized by increased but manageable hematologic toxicities, specifically neutropenia and thrombocytopenia.
